Login / Signup

Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells.

Sara PescatoriStefano LeoneManuela CipollettiStefania BartoloniAlessandra di MasiFilippo Acconcia
Published in: Journal of experimental & clinical cancer research : CR (2022)
CHK1 could be considered as an appealing novel pharmacological target for the treatment of luminal primary and MBCs.
Keyphrases
  • wild type
  • breast cancer cells
  • poor prognosis
  • squamous cell carcinoma
  • small cell lung cancer
  • dna damage response
  • signaling pathway
  • binding protein
  • endoplasmic reticulum